Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price rose 15.4% during trading on Wednesday . The company traded as high as C$0.24 and last traded at C$0.23. Approximately 504,843 shares traded hands during mid-day trading, a decline of 19% from the average daily volume of 624,324 shares. The stock had previously closed at C$0.20.
Hemostemix Stock Up 12.8 %
The company has a market cap of C$19.17 million, a P/E ratio of -11.00 and a beta of 0.20. The firm has a fifty day moving average price of C$0.10 and a 200 day moving average price of C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- How to Invest in the FAANG Stocks
- How Do Stock Buybacks Affect Shareholders?
- Financial Services Stocks Investing
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
- Best Stocks Under $10.00
- What Goldman Sachs’ Quarterly Results Reveal About the Economy
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
